• No results found

[PDF] Top 20 THE TREATMENT OF FAMILIAL HYPERCHOLESTEROLEMIA WITH A PLANT STEROL

Has 10000 "THE TREATMENT OF FAMILIAL HYPERCHOLESTEROLEMIA WITH A PLANT STEROL" found on our website. Below are the top 20 most common "THE TREATMENT OF FAMILIAL HYPERCHOLESTEROLEMIA WITH A PLANT STEROL".

THE TREATMENT OF FAMILIAL HYPERCHOLESTEROLEMIA WITH A PLANT STEROL

THE TREATMENT OF FAMILIAL HYPERCHOLESTEROLEMIA WITH A PLANT STEROL

... bow a concentration of chobesterob in the serum as does a low- or cholesterol-free diet with added sitosterol. There was no weight loss in either child during the course[r] ... See full document

5

Optimal management of familial hypercholesterolemia: treatment and management strategies

Optimal management of familial hypercholesterolemia: treatment and management strategies

... Familial hypercholesterolemia is a serious genetic dis- order affecting patients in the early years of ...Various treatment options are available at the ... See full document

10

Familial Hypercholesterolemia: From Diagnosis to Treatment

Familial Hypercholesterolemia: From Diagnosis to Treatment

... Familial hypercholesterolemia (FH) is an inherited common autosomal Mendelian disorder of lipoprotein metabolism with a population prevalence of 1 in ...and treatment of FH patients will reduce ... See full document

11

Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia

Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia

... the treatment of adult patients with heterozygous familial hypercholesterolemia (heFH), as the result of numerous studies in patients with primary hypercholesterolemia or ... See full document

15

Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia

Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia

... Abstract: Familial hypercholesterolemia (FH) is an autosomal dominant condition with a population prevalence of one in 300–500 (heterozygous) that is characterized by high levels of low-density lipoprotein ... See full document

9

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives

... Heterozygous familial hypercholesterolemia (FH) is a genetic disorder character- ized by high low-density lipoprotein cholesterol levels from birth, which exposes the arteries to high levels of atherogenic ... See full document

9

<p>Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients</p>

<p>Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients</p>

... In the post-hoc analysis of the FOURIER trial, which included 27,564 participants, the effects of adding evolocu- mab (either 140 mg subcutaneously every 2 weeks or 420 mg subcutaneously monthly) versus matching placebo ... See full document

8

Extracorporeal LDL-Cholesterol Elimination in the Treatment of Severe Familial Hypercholesterolemia

Extracorporeal LDL-Cholesterol Elimination in the Treatment of Severe Familial Hypercholesterolemia

... The plasma exchange was the initial method used in the treatment at our department. The cholesterol level at the start is given in the Graph 2. The technique was carried out in weekly interval as far as possible, ... See full document

5

Treatment of Familial Hypercholesterolemia in Children and Adolescents: Effect of Lovastatin

Treatment of Familial Hypercholesterolemia in Children and Adolescents: Effect of Lovastatin

... Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: lack of effect on low-density lipoprotein concentrations or turnover. Ducobu J, Brasseur D, Chaudron JM,[r] ... See full document

12

Long-term Treatment of Severe Familial Hypercholesterolemia in Children: Effect of Sitosterol and Bezafibrate

Long-term Treatment of Severe Familial Hypercholesterolemia in Children: Effect of Sitosterol and Bezafibrate

... Seven prepubertal children (age range 5.3 to 10.8 years) with severe heterozygous familial hyper- cholesterolemla (serum cholesterol concentration 416 ± 85 mg/dL and low-density lipoprot[r] ... See full document

7

Psychosocial Function During Treatment for Familial Hypercholesterolemia

Psychosocial Function During Treatment for Familial Hypercholesterolemia

... It has been suggested that the identification of children who are at risk for cardiovascular disease is unnecessary and may be harmful.9”#{176} Thus, some au- thors disagree with the exp[r] ... See full document

9

NOVEL THERAPEUTIC OPTIONS FOR FAMILIAL HYPERCHOLESTEROLEMIA

NOVEL THERAPEUTIC OPTIONS FOR FAMILIAL HYPERCHOLESTEROLEMIA

... Flu-like symptoms were also more often reported in the mipomersen group than in the placebo group in most studies. The flu-like symptoms usually appear shortly after mipomersen administration, but resolve within 1–2 ... See full document

8

Inhibition of Sterol Biosynthesis Reduces Tombusvirus Replication in Yeast and Plants

Inhibition of Sterol Biosynthesis Reduces Tombusvirus Replication in Yeast and Plants

... the sterol biosynthesis genes ERG25 and ERG4 affected the replication of Tomato bushy stunt virus (TBSV) in a yeast model ...the sterol biosynthesis inhibitor lovastatin reduced TBSV replication by 4-fold, ... See full document

12

The genetics of familial hypercholesterolemia and emerging therapies

The genetics of familial hypercholesterolemia and emerging therapies

... Especially if LDL-C is not markedly elevated, the detection of a causative mutation is important for treatment decisions. An effective and cost-effective way is cascade screening. The first diagnosed patient is ... See full document

10

Molecular Diagnosis of Familial Hypercholesterolemia

Molecular Diagnosis of Familial Hypercholesterolemia

... 22-Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation and treatment of high blood cholesterol in adults (Adult treatment Panel III). JAMA 2001 May 16; ... See full document

12

Improving the genetic diagnosis of familial hypercholesterolemia

Improving the genetic diagnosis of familial hypercholesterolemia

... Importantly, therapeutic implications from genetic testing can also occur when LALD (bi-allelic variants in LIPA) and sitosterolemia (bi-allelic variants in ACBG5/8) phenocopy cases are identified. Statins are not ... See full document

132

The genetic basis of familial hypercholesterolemia: inheritance, linkage, and mutations

The genetic basis of familial hypercholesterolemia: inheritance, linkage, and mutations

... Abstract: Familial hypercholesterolemia (FH) is a genetic disorder of lipoprotein metabolism characterized by high plasma concentrations of low-density lipoprotein cholesterol (LDLc), tendon xanthomas, and ... See full document

12

Correlating corneal arcus with atherosclerosis in familial hypercholesterolemia

Correlating corneal arcus with atherosclerosis in familial hypercholesterolemia

... (mean age 13 ± 12) than those with arcus (mean age 31 ± 11). The data on these 17 patients was collected over sev- eral decades and in some cases is ongoing. With the advent of newer therapies such as LDL removal by ... See full document

9

Genetic screening for homozygous and heterozygous familial hypercholesterolemia

Genetic screening for homozygous and heterozygous familial hypercholesterolemia

... Abstract: Familial hypercholesterolemia (FH) is a common inherited disorder that results in premature ...of treatment can modify disease progression and ...mutations. Familial defective Apo B ... See full document

11

Association between non cholesterol sterol concentrations and Achilles tendon thickness in patients with genetic familial hypercholesterolemia

Association between non cholesterol sterol concentrations and Achilles tendon thickness in patients with genetic familial hypercholesterolemia

... lipid-lowering treatment modifies the development of xanthomas and the subjects of our study, although they were untreated at the time of analysis, most of them had variable time with statins that may have altered ... See full document

9

Show all 10000 documents...